Longterm course of neuropsychological symptoms and ME/CFS after SARS-CoV-2-infection: a prospective registry study.
Reuken, P A, Besteher, B, Finke, K et al. · European archives of psychiatry and clinical neuroscience · 2024 · DOI
Quick Summary
This study followed over 1,000 people who had long-lasting symptoms after COVID-19 infection. Researchers found that about 31% of patients met the diagnostic criteria for ME/CFS at their first visit, but this dropped to 19% at a second visit months later. While patients reported feeling less fatigued and having fewer concentration problems over time, many continued to experience long-lasting symptoms that significantly affected their daily lives.
Why It Matters
This study provides important real-world data showing that ME/CFS affects a substantial minority of COVID-19 survivors and that symptoms often persist long-term. Understanding the natural history and prevalence of post-COVID ME/CFS helps validate the condition as a significant clinical problem and may inform development of targeted interventions for this patient population.
Observed Findings
31.3% of post-COVID patients met ME/CFS criteria at first visit (median 255 days post-infection), declining to 19.4% at second visit (median 402 days)
95.5% of included patients reported polysymptomatic disease
Self-reported fatigue decreased from 83.7% to 72.7% between visits
Self-reported concentration impairment decreased from 66.2% to 57.9% between visits
Structured screening showed non-significant changes in neuropsychological symptoms over time
Inferred Conclusions
A significant proportion of SARS-CoV-2 survivors presenting with ongoing symptoms meet ME/CFS diagnostic criteria
Self-reported symptom severity tends to decrease over time, though a substantial proportion of patients experience persistent long-lasting symptoms
There is a discrepancy between subjective symptom reports and objective structured screening measures, suggesting the need for careful clinical assessment
New therapeutic approaches are needed to address the persistent symptoms affecting this patient population
Remaining Questions
What factors predict which patients will experience persistent ME/CFS versus those who recover?
What This Study Does Not Prove
This study does not establish causation or mechanisms linking COVID-19 to ME/CFS, nor does it evaluate the effectiveness of any specific treatments. The decline in self-reported symptoms does not necessarily mean patients have recovered functionally, and the discrepancy between self-report and structured screening suggests the true clinical picture may be more complex than perceived by patients alone.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.